Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

NCT05360537 on ClinicalTrials.gov · last registry update 2023-12-15

Finished 1 December 2021, after enrolling 100 people. Primary outcome, as filed: Change of Time in Range % at 7 days, at 1 and 6 months. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Palermo
Sponsor type: Other
Enrollment: 100
Started: 2021-04-01
Primary completion: 2021-12-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change of Time in Range % at 7 days, at 1 and 6 months

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.